Evidence map›Paper›PMID 42105088›Full record

ArticleAnnals of hematology2026

Impact of diagnosis-to-treatment interval on the outcome of patients with acute myeloid leukemia.

Samah Nassereddine, Yuan Feng, Jordan Selep, Firas El Chaer, Leah Wells, Ramey Elsarrag, Kimberly Doucette, Vanya Aggarwal, Lacey Williams, Imad Tabbara and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Samah NassereddineGW Cancer Center, George Washington University, Washington, DC, USA.
Yuan FengDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Jordan SelepGW Cancer Center, George Washington University, Washington, DC, USA.
Firas El ChaerDivision of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Leah WellsDivision of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Ramey ElsarragDivision of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Kimberly DoucetteDepartment of Medicine, Georgetown University, Washington, DC, USA.
Vanya AggarwalGW Cancer Center, George Washington University, Washington, DC, USA.
Lacey WilliamsDivision of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Imad TabbaraGW Cancer Center, George Washington University, Washington, DC, USA.
Shanshan LiuDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Guoquing DiaoDepartment of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
Mary-Elizabeth M PercivalClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Catherine LaiDivision of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Catherine.lai@pennmedicine.upenn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is considered an oncologic emergency, yet the optimal timing for treatment initiation remains uncertain. We conducted a multi-institutional retrospective study of 698 adults with newly diagnosed AML presenting to four academic centers across the United States. Diagnosis-to-treatment intervals (DTI) were categorized as < 5 days, 5-10 days, and > 10 days. Outcomes were analyzed using multivariable models adjusting for age, treatment intensity, ELN 2017 risk classification, and white blood cell count. Among younger patients, DTI was not associated with differences in survival outcomes. In contrast, older patients demonstrated improved survival with delayed treatment (DTI > 10 days), particularly those with lower white blood cell counts. No adverse effects from treatment delay were observed in younger cohorts. This retrospective study showed that prolonged DTI is associated with improved survival in older adults with newly diagnosed AML, challenging the traditional assumption that immediate therapy universally improves outcomes. These findings underscore the importance of individualized treatment timing in the era of precision oncology.

Indexed as

Leukemia, Myeloid, AcuteTime-to-TreatmentAdultAgedAged, 80 and overAge FactorsFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment DelayTreatment OutcomeAcute myeloid leukemiaDiagnosis-to-treatment intervalInduction chemotherapyMolecular testingPrecision medicineRisk stratificationTargeted therapyTreatment outcomes

Identifiers

PMID42105088
PMCPMC13323866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.